As of the 18th of February 2026, Spermosens has the Coefficient Of Variation of 495.82, risk adjusted performance of 0.1696, and Variance of 18702.26. Spermosens technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. Please validate Spermosens ABcoefficient of variation, variance, and the relationship between the mean deviation and standard deviation to decide if Spermosens is priced more or less accurately, providing market reflects its prevalent price of 0.0012 per share.
Spermosens' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Spermosens' valuation are provided below:
Market Capitalization
634.6 K
There are over thirty-nine available fundamental trend indicators for Spermosens AB, which can be analyzed over time and compared to other ratios. Active traders should verify all of Spermosens AB current fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
The current Net Loss is estimated to decrease to about (9.6 M). The current Net Loss is estimated to decrease to about (9.6 M).
Spermosens
Net Income
Change In Cash
Net Borrowings
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Depreciation
Capital Expenditures
Total Cash From Operating Activities
Issuance Of Capital Stock
Net Income
End Period Cash Flow
Other Non Cash Items
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Common Stock Shares Outstanding
Non Current Liabilities Total
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Short Long Term Debt
Total Current Assets
Capital Stock
Net Working Capital
Intangible Assets
Net Interest Income
Interest Expense
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Research Development
Probability Of Bankruptcy
The Net Income trend for Spermosens AB offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Spermosens is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Spermosens' Net Income Growth Pattern
Below is the plot of the Net Income of Spermosens AB over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Spermosens AB financial statement analysis. It represents the amount of money remaining after all of Spermosens AB operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Spermosens' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spermosens' overall financial position and show how it may be relating to other accounts over time.
Understanding that Spermosens' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Spermosens represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Spermosens' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Spermosens 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Spermosens' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Spermosens.
0.00
11/20/2025
No Change 0.00
0.0
In 3 months and 1 day
02/18/2026
0.00
If you would invest 0.00 in Spermosens on November 20, 2025 and sell it all today you would earn a total of 0.00 from holding Spermosens AB or generate 0.0% return on investment in Spermosens over 90 days. Spermosens is related to or competes with WuXi AppTec, Thermo Fisher, Danaher, Danaher, Siemens Healthineers, SIEMENS HEALTH, and IDEXX Laboratories. Spermosens is entity of Germany. It is traded as Stock on F exchange. More
Spermosens Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Spermosens' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Spermosens AB upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Spermosens' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Spermosens' standard deviation. In reality, there are many statistical measures that can use Spermosens historical prices to predict the future Spermosens' volatility.
Spermosens is out of control given 3 months investment horizon. Spermosens AB owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.2, which indicates the firm had a 0.2 % return per unit of risk over the last 3 months. We were able to interpolate twenty-four different technical indicators, which can help you to evaluate if expected returns of 26.59% are justified by taking the suggested risk. Use Spermosens AB Variance of 18702.26, risk adjusted performance of 0.1696, and Coefficient Of Variation of 495.82 to evaluate company specific risk that cannot be diversified away. Spermosens holds a performance score of 15 on a scale of zero to a hundred. The entity has a beta of -4.72, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Spermosens are expected to decrease by larger amounts. On the other hand, during market turmoil, Spermosens is expected to outperform it. Use Spermosens AB market risk adjusted performance, coefficient of variation, jensen alpha, as well as the relationship between the mean deviation and standard deviation , to analyze future returns on Spermosens AB.
Correlation Coefficient
0.0
Spearman Rank Test
0.99
Residual Average
0.0
Price Variance
0.0
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
At this time, Spermosens' Net Interest Income is most likely to decrease significantly in the upcoming years.
Based on the recorded statements, Spermosens AB reported net income of (10.2 Million). This is 102.99% lower than that of the Healthcare sector and 105.89% lower than that of the Diagnostics & Research industry. The net income for all Germany stocks is 101.79% higher than that of the company.
Spermosens Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spermosens' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spermosens could also be used in its relative valuation, which is a method of valuing Spermosens by comparing valuation metrics of similar companies.
Spermosens is currently under evaluation in net income category among its peers.
The Macroaxis Fundamental Analysis modules help investors analyze Spermosens AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spermosens using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spermosens AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Other Information on Investing in Spermosens Stock
Spermosens financial ratios help investors to determine whether Spermosens Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spermosens with respect to the benefits of owning Spermosens security.